CAMBRIDGE, England--(BUSINESS WIRE)--Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with one of the world’s leading pharmaceutical companies to develop, manufacture and distribute a new companion diagnostic assay for the detection of specific mutations in colorectal cancer samples to select patients for the partner’s therapeutic monoclonal antibody.
